Adjuvant denosumab for early breast cancer–Evidence and controversy

IF 5.7 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Pub Date : 2024-10-23 DOI:10.1016/j.breast.2024.103826

Laura Moretti , Laura Richelmi , Deborah Cosentini, Rebecca Pedersini, Salvatore Grisanti, Vito Amoroso, Alfredo Berruti, Marta Laganà

引用次数: 0

Abstract

The efficacy of adjuvant denosumab in combination with hormonotherapy in breast cancer patients was investigated in two randomized trials, ABCSG-18 and D-Care, but the results were mixed with respect to the impact of this drug on disease-free survival. However, the ABCSG-18 study has achieved its primary goal: prevention of clinical fractures. Therefore, the protective role of Denosumab on bone fragility induced by estrogen deprivation, already demonstrated in post-menopausal women, has been validated in the breast cancer setting.

查看原文本刊更多论文

辅助治疗早期乳腺癌的地诺单抗--证据与争议。

ABCSG-18和D-Care两项随机试验研究了地诺单抗联合激素疗法对乳腺癌患者辅助治疗的疗效，但该药物对无病生存期的影响结果不一。不过，ABCSG-18 研究实现了其主要目标：预防临床骨折。因此，地诺单抗对雌激素缺乏引起的骨脆性的保护作用已在绝经后妇女中得到证实，在乳腺癌患者中也得到了验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast 医学-妇产科学

CiteScore

8.70

自引率

2.60%

发文量

165

审稿时长

59 days

期刊介绍： The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.